Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status
出版年份 2015 全文链接
标题
Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 8, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-05-16
DOI
10.1186/s13045-015-0151-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial†
- (2014) Q. Zhou et al. ANNALS OF ONCOLOGY
- Customized Adjuvant Phase II Trial in Patients With Non–Small-Cell Lung Cancer: IFCT-0801 TASTE
- (2014) Marie Wislez et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data
- (2014) LANCET
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
- (2013) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Surgery for NSCLC in the era of personalized medicine
- (2013) Tetsuya Mitsudomi et al. Nature Reviews Clinical Oncology
- Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Non–Small-Cell Lung Cancer
- (2012) Eva E. Schaake et al. JOURNAL OF CLINICAL ONCOLOGY
- Influence of Chemotherapy onEGFRMutation Status Among Patients With Non–Small-Cell Lung Cancer
- (2012) Hua Bai et al. JOURNAL OF CLINICAL ONCOLOGY
- Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? -- A literature-based meta-analysis
- (2012) Chongrui Xu et al. Journal of Hematology & Oncology
- Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status
- (2012) She-Juan An et al. PLoS One
- Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design
- (2011) J. E. Chaft et al. CLINICAL CANCER RESEARCH
- Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
- (2011) Qing Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non–Small-Cell Lung Cancer
- (2011) Giorgio V. Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- Erlotinib-Based Perioperative Adjuvant Therapy for a Case of Unresectable Stage IIIA (N2) Nonsmall Cell Lung Cancer
- (2010) Qiming Wang et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy
- (2010) Song Dong et al. Journal of Hematology & Oncology
- Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer
- (2009) Humberto Lara-Guerra et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
- (2009) Kathy S Albain et al. LANCET
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment
- (2008) T. M. Chin et al. CLINICAL CANCER RESEARCH
- Neoadjuvant (Induction) Erlotinib Response in Stage IIIA Non–Small-Cell Lung Cancer
- (2008) Ingrid Kappers et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started